National Pension Service Has $65.03 Million Stock Holdings in Illumina, Inc. $ILMN

National Pension Service raised its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 246.7% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 369,856 shares of the life sciences company’s stock after acquiring an additional 263,172 shares during the period. National Pension Service owned approximately 0.24% of Illumina worth $65,032,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in ILMN. HighPoint Advisor Group LLC grew its stake in shares of Illumina by 3.7% during the fourth quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock worth $291,000 after purchasing an additional 80 shares during the period. Elevation Wealth Partners LLC lifted its stake in Illumina by 52.5% in the second quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after buying an additional 84 shares during the period. Meeder Advisory Services Inc. boosted its holdings in Illumina by 3.1% during the first quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock worth $348,000 after buying an additional 85 shares during the last quarter. Toronto Dominion Bank boosted its holdings in Illumina by 0.3% during the fourth quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock worth $4,407,000 after buying an additional 92 shares during the last quarter. Finally, Panagora Asset Management Inc. grew its position in shares of Illumina by 3.9% during the 4th quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock worth $333,000 after buying an additional 96 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on ILMN shares. Canaccord Genuity Group upped their price target on Illumina from $190.00 to $205.00 and gave the company a “hold” rating in a research note on Monday, August 3rd. Guggenheim lifted their price objective on shares of Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Piper Sandler restated an “overweight” rating and set a $225.00 price objective (up from $200.00) on shares of Illumina in a report on Monday, August 3rd. Royal Bank Of Canada upped their target price on shares of Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Finally, Evercore reiterated an “outperform” rating on shares of Illumina in a report on Monday, July 6th. Ten investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $199.12.

Illumina Trading Up 2.6%

NASDAQ ILMN opened at $206.45 on Friday. The firm has a market cap of $31.17 billion, a P/E ratio of 38.52, a P/E/G ratio of 2.85 and a beta of 1.46. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The stock’s 50-day moving average is $200.89 and its 200-day moving average is $162.18. Illumina, Inc. has a one year low of $88.00 and a one year high of $231.81.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. During the same quarter in the previous year, the business posted $1.19 EPS. Illumina’s revenue for the quarter was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Sell-side analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Keith Meister sold 457,858 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the transaction, the director owned 2,372,694 shares in the company, valued at $474,776,069.40. This represents a 16.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 2,062,465 shares of company stock valued at $436,589,802 over the last 90 days. Insiders own 2.90% of the company’s stock.

About Illumina

Illumina, Inc develops and manufactures genomic analysis technologies used by researchers, healthcare providers, pharmaceutical companies and other organizations. Its offerings include next-generation DNA sequencing systems, microarray platforms, consumables, laboratory services and bioinformatics software designed to help analyze genetic variation and biological functions.

The company’s sequencing instruments include systems for a range of applications and throughput levels, such as the NovaSeq, NextSeq, MiSeq and iSeq platforms.